Prevalence of Physiological, Pathological and Behavioral Risk Factors in Patients Treated with Antidiabetic Sulfonylureas

1. Guariguata L, Whiting DR, Hambleton I et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diab Res Clin Pract. 2014;103(2):137-149.10.1016/j.diabres.2013.11.00224630390Search in Google Scholar

2. Sonia TA, Sharma CP. Oral Delivery of Insulin. Woodhead Publishing. 2014. 1-57.10.1533/9781908818683.1Search in Google Scholar

3. Virally M, Blickle JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes melliuts: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diab Metab. 2007;33:231-244.10.1016/j.diabet.2007.07.00117703979Search in Google Scholar

4. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metab Clin Experim. 2006;55(Suppl 1): S20-S27.10.1016/j.metabol.2006.02.00316631807Search in Google Scholar

5. Germino FW. Noninsulin Treatment of Type 2 Diabetes mellitus in Geriatric Pacients: A review. Clin Therap. 2011; 33(12):1868-1882.10.1016/j.clinthera.2011.10.02022136979Search in Google Scholar

6. Solet JL, Baroux N, Pochet M, et al. Prevalence of type 2 diabetes and other cardiovascular risk factors in Mayotte in 2008: The Maydia study, Diabetes & Metabolism. 2011;37:201-207.Search in Google Scholar

7. Foster DW. Diabetul zaharat. In: Harrison – Principiile medicinei interne. Bucharest, Romania: Teora, 2003. 2265-2294.Search in Google Scholar

8. Belhatem N, Mohammedi K, Rouzet F, et al. Impact of morbid obesity on the kidney function of patientis with type 2 diabetes. Diabetes Res and Clin Pract. 2015;108(1):143-149.10.1016/j.diabres.2015.01.02825666105Search in Google Scholar

9. Fukui M, Tanaka M, Toda H, et al. Risk factors for the developement of diabetes mellitus, hypertension and dyslipidemia. Diabetes Res and Clin Pract. 2011,94(1):15-18.10.1016/j.diabres.2011.07.00621802759Search in Google Scholar

10. Samaranayaka S, Gulliford MC. Trends in cardiovascular risk factors among people with diabetes in a population based study, Health survey for England 1994-2009. Primary Care Diabetes. 2013;7(3):193-198.10.1016/j.pcd.2013.04.01023685024Search in Google Scholar

11. Taskinen MR, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239(2): 483-495.10.1016/j.atherosclerosis.2015.01.03925706066Search in Google Scholar

12. Lastra G, Syed S, Kurukulasuriya LR et al., Type 2 Diabetes Mellitus and Hypertension: An Update. Endocrinology and Metabolism Clinics of North America. 2014;43(1):103-122.10.1016/j.ecl.2013.09.005394266224582094Search in Google Scholar

13. Frontoni S, Solini A, Fioretto P, et al. The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint. Nutrition, Metabolism and Cardiovascular Diseases. 2014;24(6):577-584.10.1016/j.numecd.2014.01.00424582686Search in Google Scholar

14. Wei X, Meng E, Sufang Yu. A meta-analysis of passive smoking and risk of developing type 2 diabetes mellitus. Diabetes Res and Clin Pract. 2015;107(1):9-14.10.1016/j.diabres.2014.09.01925488377Search in Google Scholar